{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:40:40Z","timestamp":1790984440396,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.beha.2004.03.001","type":"journal-article","created":{"date-parts":[[2004,5,31]],"date-time":"2004-05-31T11:09:05Z","timestamp":1086001745000},"page":"77-87","source":"Crossref","is-referenced-by-count":18,"title":["Low- and ultra-low-molecular-weight heparins"],"prefix":"10.1016","volume":"17","author":[{"given":"Ajay K","family":"Kakkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2004.03.001_BIB1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0140-6736(72)91595-4","article-title":"Efficacy of low doses of heparin in prevention of deep vein thrombosis after major surgery","volume":"2","author":"Kakkar","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2004.03.001_BIB2","first-page":"45","article-title":"Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an International Multicentre Trial","volume":"2","author":"Kakkar","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2004.03.001_BIB3","first-page":"651","article-title":"Molecular weight dependence of the anticoagulant properties of heparin","volume":"16","author":"Lane","year":"1979","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.beha.2004.03.001_BIB4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low molecular weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.284.6313.375","article-title":"Low molecular weight heparin and prevention of postoperative deep vein thrombosis","volume":"284","author":"Kakkar","year":"1982","journal-title":"BMJ"},{"key":"10.1016\/j.beha.2004.03.001_BIB6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/bjs.1800840605","article-title":"Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention","volume":"84","author":"Koch","year":"1997","journal-title":"The British Journal of Surgery"},{"key":"10.1016\/j.beha.2004.03.001_BIB7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0140-6736(92)93223-A","article-title":"Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis","volume":"340","author":"Nurhomed","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2004.03.001_BIB8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bmj.309.6950.299","article-title":"Comparison of efficacy of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis","volume":"309","author":"Leizorovicz","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.beha.2004.03.001_BIB9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-130-10-199905180-00003","article-title":"Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomised, controlled trials","volume":"130","author":"Gould","year":"1999","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJM200103013440902","article-title":"Effects of low molecular weight heparin on thrombus regression and recurrent thromboembolism in patients with deep vein thrombosis","author":"Breddin","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB11","first-page":"449","article-title":"Long term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis","volume":"96","author":"Hull","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.03.001_BIB12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199603143341101","article-title":"A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis","volume":"334","author":"Levine","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199603143341102","article-title":"Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital compared with subcutaneous low molecular weight heparin administered at home. The Tasman Study Group","volume":"334","author":"Koopman","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJM199709043371001","article-title":"Low molecular weight heparin in the treatment of patients with venous thromboembolism","volume":"337","year":"1997","journal-title":"The New England Journal of Medicine"},{"issue":"supplement II","key":"10.1016\/j.beha.2004.03.001_BIB15","first-page":"51","article-title":"Subcutaneous low molecular weight heparin (IMM) against unfractionated (UF) heparin for prophylaxis of thromboembolism in medical patients","volume":"68","author":"Harenberg","year":"1995","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.beha.2004.03.001_BIB16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199909093411103","article-title":"A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group","volume":"341","author":"Samama","year":"1999","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB17","unstructured":"Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus P. Goldhaber SZ for the PREVENT Medical Thromboprophylaxis Study Group. A randomised placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ISTH abstract OC396. Presented on 18 July 2003 in Birmingham, UK."},{"key":"10.1016\/j.beha.2004.03.001_BIB18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low molecular weight heparin during instability in coronary artery disease","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2004.03.001_BIB19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low molecular weight heparin with unfractionated heparin investigators for unstable coronary artery disease","volume":"337","year":"1997","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1055\/s-0037-1613136","article-title":"Variation in relative risk of venous thromboembolism in different cancer","volume":"87","author":"Thodiyil","year":"2002","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.beha.2004.03.001_BIB21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0002-9610(70)80023-X","article-title":"Deep vein thrombosis of the leg: is there a high risk group?","volume":"120","author":"Kakkar","year":"1970","journal-title":"American Journal of Surgery"},{"key":"10.1016\/j.beha.2004.03.001_BIB22","article-title":"Prevention of perioperative venous thromboembolism: outcome after cancer and non-cancer surgery","author":"Kakkar","year":"2001","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.beha.2004.03.001_BIB23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(00)05249-1","article-title":"Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta analysis of the randomised trials","volume":"358","author":"Eikelboom","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2004.03.001_BIB24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"Bergqvist","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB25","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.03.001_BIB26","first-page":"491(a)","article-title":"Treatment of deep vein thrombosis in cancer: a comparison of unfractionated low molecular weight heparin","volume":"96","author":"Kakkar","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2004.03.001_BIB27","first-page":"1","article-title":"Low molecular weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"125","author":"Lee","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB28","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/0140-6736(92)92064-M","article-title":"Lower mortality in cancer patients treated with low molecular weight versus standard heparin","volume":"339","author":"Green","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2004.03.001_BIB29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0002-9343(97)89484-3","article-title":"Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis","volume":"100","author":"Siragusa","year":"1996","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2004.10.002","article-title":"Low molecular weight heparin (LMWH) therapy and survival in advanced cancer","author":"Kakkar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2004.03.001_BIB31","unstructured":"Lee AYY. ASCO abstract book. 2003."},{"key":"10.1016\/j.beha.2004.03.001_BIB32","unstructured":"Altinbas HSC, Er O, Ozkan M, et al, Prospective randomised study of epirubicine cyclophosphamide and vincristine. Combination chemotherapy (CEV), low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). ASCO annual meeting 2001. Abstract no. 1280."},{"issue":"supplement 1","key":"10.1016\/j.beha.2004.03.001_BIB33","article-title":"Malignancy and low molecular weight heparin therapy: the MALT trial","volume":"1","author":"Klerk","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"6319m, supplement","key":"10.1016\/j.beha.2004.03.001_BIB34","first-page":"30","article-title":"Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs","volume":"350","author":"Petitou","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.beha.2004.03.001_BIB35","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2004.03.001_BIB36","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2004.03.001_BIB37","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB38","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB39","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery","volume":"162","author":"Turpie","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB40","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archinte.163.11.1337","article-title":"Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery","volume":"163","author":"Eriksson","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB41","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2004.03.001_BIB42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/18877","volume":"398","author":"Petitou","year":"1999","journal-title":"Letters Nature"},{"issue":"supplement 2","key":"10.1016\/j.beha.2004.03.001_BIB43","first-page":"181","article-title":"Identification of heparin cofactor II as the principle plasma cofactor for pentosan polysulfate (SP54)","volume":"17","author":"Scully","year":"1991","journal-title":"Thrombosis and Haemostasis"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692604000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692604000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T10:56:31Z","timestamp":1549536991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692604000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S1521692604000040"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2004.03.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}